吡柔比星辅助化疗方案治疗老年人恶性淋巴瘤的疗效及安全性分析.docVIP

毗柔比星辅助化疗方案治疗老年人恶性淋巴瘤的疗效及安全性分析 赵水平 (巩义市人民医院肿瘤血液科河南郑州451200) 【摘要】R的：探讨毗柔比星辅助化疗方案治疗老年人恶性淋巴瘤的疗效及 安全性。方法：选取91例老年恶性淋巴瘤患者为研究对象，根据患者意愿分成 联合组(AS, n=50)和化疗组(B组，n=41)两组。比对两组患者临床疗效及 不良反应发生情况。结果：①治疗后，A组总有效率为84.0%,明显高于B组的 53.7%,对比差异明显(Plt;0.05);②A组不良反应发生率为40.0%,明显低于B 组的63.4%,对比差异明显(Plt;0.05)o结论：对老年恶性淋巴瘤患者予以毗柔 比星辅助化疗方案，疗效确切，值得临床推广。 【关键词】毗柔比星；化疗；老年；恶性淋巴瘤；安全性 【屮图分类号】R453 【文献标识码】A 【文章编 号】2095-1752 (2015) 03-0062-02 Pyrazole soft star than the curative effect of adjuvant chemotherapy regimen for the elderly malignant lymphoma and safety analysis Zhao Shuiping, Gongyi city peoples hospital of tumor onset, 451200,China [Abstract] Objective Explore pyrazole soft than star adjuvant chemotherapy regimen for the elderly efficacy and safety of malignant lymphoma. Methods Select 91 cases senile patients with malignant lymphoma as the research object, according to their willingness to into joint group (group A, n = 50) and chemotherapy group (group B, n = 41) in the two groups. Compare two groups of patients with clinical efficacy and adverse reactions occur. Results (1) after treatment, the total effective rate of group A was 84.0%, significantly higher than the 53.7% of the group B, compared with significant difference (Plt;0.05); (2) the incidence of adverse reaction of group A was 40.0%, significantly less than 63.4% of the group B, compared with significant difference (Plt;0.05). Conclusion Pyrazole soft to elderly patients with malignant lymphoma than star adjuvant chemotherapy scheme, curative effect, worth clinical promotion. 【Key words］ Pyrazole soft than star; Chemotherapy; Old age; Malignant lymphoma; Security 淋巴瘤是一种起源于淋巴造血系统的恶性肿瘤，临床猜测苏同基因突变、病 毒感染或合并自身免疫系统疾病等相关［1】。据不完全资料统计，我国近年来该 疾病发病率呈逐年递增趋势，现已引起临床广泛关注。部分研究者认为呲柔比星 作为蒽环类药物，药毒性较低，且抗肿瘤谱广，对提高恶性淋巴瘤的临床疗效具 有积极影响。本次研宄为证实上述结论的准确性，选取91例老年患者为研究对 象，现报告如下。 资料与方法 一般资料 选取我院于2010年3月一2014年3月收治的91例老年恶性淋巴瘤患者为 研宄对象，均通过血生化、活检、脑脊液检查及病理学检查等，符合《临床肿瘤 学》［2］中相关诊断标准，被确诊为恶性淋巴瘤。本次受试患者中男55例，女36 例；年龄65?77岁，平均(70.5plusmn;2.6)岁；合并高血压者55例，糖尿病 者27例；类型：非霍奇金淋巴瘤52例，霍奇